REG - Intnl. Biotechnology - Partnership Agreement with Schroders Capital

International Biotechnology TrustAnnouncement

02/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251002:nRSB7160Ba&default-theme=true

RNS Number : 7160B  Intl. Biotechnology Trust PLC  02 October 2025

INTERNATIONAL BIOTECHNOLOGY TRUST PLC

(the "Company")

 

 

Partnership Agreement with Schroders Capital

 

The Company's investment policy is to invest in a diversified portfolio of
companies whose shares are considered to have growth prospects consistent with
the objective of achieving long-term capital growth. The majority of the
Company's assets are invested in the quoted biotechnology sector with a
limited exposure, within a range of 5-15% of portfolio value, to unquoted
companies, primarily through private funds.

 

The Company currently has unquoted exposures of c.8.4% of portfolio
value((1)), which predominantly consists of two funds managed by SV Health
Partners. There are no anticipated changes to these existing holdings, which
have produced strong performance, and will remain outside of the Partnership.

 

Today, the Company announces that it has entered into an agreement with
Schroders Capital to establish a partnership (the "Partnership") through which
the Company intends over time to invest in further unquoted biotechnology
opportunities.((2))

 

It is intended that the Company will make an initial commitment to the
Partnership of £10 million, c.4% of current portfolio value((2)), which over
time will be committed to funds investing in unquoted biotechnology companies.
It is the Board's intention that over the long-term the Partnership will
provide Shareholders with access to a portfolio of innovative earlier-stage
companies through unquoted funds, diversified by underlying manager, vintage
and geography.

 

Schroders Capital has built a track record of more than 25 years in the
healthcare and biotechnology sectors, committing over $4.3 billion
(approximately £3.5 billion) across nearly 700 investments worldwide. During
this time, Schroders Capital has cultivated strong relationships with leading
healthcare and biotechnology managers across North America, Europe, and Asia.
Building on this foundation, Schroders Capital seeks to invest in and
alongside biotechnology managers with proven track records of exceptional
long-term value generation, strong scientific and medical expertise,
disciplined investment practices, and access to differentiated opportunities
that have the potential to significantly improve global healthcare outcomes.

 

Under the Partnership agreement, Schroders Capital is entitled to a management
fee of 0.9% per annum based on the asset value of the Company's investment in
the Partnership, as well as £25,000 per annum for administration costs, with
aggregate fees due to Schroders Capital in any one year being capped at 0.25%
of the Company's net asset value.

 

 

Enquiries:

 

Schroder Investment Management Limited

 Natalia de Sousa (Company Secretary)  0207 658 6000

 Charlotte Banks (Press)               0207 658 6000

 

Notes:

 

(1) As at 26 September 2025.

 

(2) Schroders Capital Management (Switzerland) has been appointed as the
investment manager to the Partnership and the Company will be its sole limited
partner.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRQFLFBEBLEFBF